Literature DB >> 16151671

Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk.

P Vestergaard1, L Rejnmark, L Mosekilde.   

Abstract

The purpose of this study was to assess alterations in fracture risk in patients with hyper- and hypothyroidism, and the effects of antithyroid drugs and levothyroxine on fracture risk. The study was designed as a case-control study. All patients with a fracture (n = 124,655) in the year 2000 in Denmark served as cases. For each case, three age- and gender-matched controls were randomly drawn from the general population (n = 373,962). Exposure variables were a diagnosis of hyperthyroidism, hypothyroidism, ever use of antithyroid drugs, and ever use of levothyroxine. Adjustments were made for time since diagnosis, surgery for hyperthyroidism, thyroid cancer, prior fracture, alcoholism, and corticosteroid use. There was an increase in the risk of any fracture within the first 5 years after a diagnosis of hyperthyroidism, and the first 10 years after a diagnosis of hypothyroidism. Use of antithyroid drugs was associated with a significantly reduced fracture risk independently of the dose used (odds ratio [OR] 0.79-0.84, 2P < 0.05). No effect of levothyroxine on fracture risk was present. Thyroid surgery for hyperthyroidism and thyroid cancer were not associated with fracture risk. A prior fracture, alcoholism, and corticosteroid use were significant risk factors for fractures. Fracture risk is increased at the time of diagnosis of both hyper- and hypothyroidism, and this increase seems reversible. Low-dose levothyroxine was not associated with fracture risk. The effect of antithyroid drugs may be caused by the reduction in thyroid hormone levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151671     DOI: 10.1007/s00223-005-0068-x

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  31 in total

1.  Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts.

Authors:  J H Duncan Bassett; Alan Boyde; Peter G T Howell; Richard H Bassett; Thomas M Galliford; Marta Archanco; Holly Evans; Michelle A Lawson; Peter Croucher; Donald L St Germain; Valerie Anne Galton; Graham R Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

Review 2.  Role and Mechanisms of Actions of Thyroid Hormone on the Skeletal Development.

Authors:  Ha-Young Kim; Subburaman Mohan
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

3.  Advanced bone formation in mice with a dominant-negative mutation in the thyroid hormone receptor β gene due to activation of Wnt/β-catenin protein signaling.

Authors:  Patrick J O'Shea; Dong Wook Kim; John G Logan; Sean Davis; Robert L Walker; Paul S Meltzer; Sheue-yann Cheng; Graham R Williams
Journal:  J Biol Chem       Date:  2012-03-22       Impact factor: 5.157

4.  Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?

Authors:  Graham R Williams
Journal:  J Endocrinol Invest       Date:  2014-06-18       Impact factor: 4.256

5.  Normalization of cortical bone density in children and adolescents with hyperthyroidism treated with antithyroid medication.

Authors:  N Numbenjapon; G Costin; P Pitukcheewanont
Journal:  Osteoporos Int       Date:  2011-12-21       Impact factor: 4.507

Review 6.  Thyroid hormone actions in cartilage and bone.

Authors:  Graham R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

7.  Anatomical Assessment of the Adult Skeleton of Zebrafish Reared Under Different Thyroid Hormone Profiles.

Authors:  Stephanie Keer; Karly Cohen; Catherine May; Yinan Hu; Sarah McMenamin; Luz Patricia Hernandez
Journal:  Anat Rec (Hoboken)       Date:  2019-04-29       Impact factor: 2.064

8.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

Review 9.  Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis.

Authors:  Christina D Wirth; Manuel R Blum; Bruno R da Costa; Christine Baumgartner; Tinh-Hai Collet; Marco Medici; Robin P Peeters; Drahomir Aujesky; Douglas C Bauer; Nicolas Rodondi
Journal:  Ann Intern Med       Date:  2014-08-05       Impact factor: 25.391

10.  Iodothyronine deiodinase enzyme activities in bone.

Authors:  Allan J Williams; Helen Robson; Monique H A Kester; Johannes P T M van Leeuwen; Stephen M Shalet; Theo J Visser; Graham R Williams
Journal:  Bone       Date:  2008-04-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.